Figure 1. Breakage-Fusion-Bridge Cycles of the Chromatid Type
This model depicts the fate of a cell in which two sister chromatids bearing the selected gene have fused after replication of a broken chromatid. At anaphase, the dicentric chromatid appears as a bridge between centromeres moving to opposite poles of the mitotic spindle. Breakage of this giant inverted repeat leaves each daughter cell with a chromatid lacking one telomere, which again fuses after replication, perpetuating the BFB cycles. Amplification occurs in one daughter cell when the breakage is asymmetric, leading to unequal distribution of the selected gene in the daughter cells. The additional copies are located on the chromosome arm bearing the original copy of this gene and are organized as megabase-long inverted repeats with one or several orders of symmetry.
is consistent with the hypothesis that breaks can trigger clastogen, while AMD induces breaks clustered at the level of a few sites, one of which is telomeric to and amplification. The observation that out of two agents selective for asparagine synthetase gene amplification, close to the mdr1 gene, an appropriate localization for triggering of mdr1 amplification. These loci are specifithe only one that is clastogenic allows the recovery of mutants amplified for this gene also supports this cally revealed on metaphase chromosome preparations from AMD-treated cells by a high frequency of gaps and interpretation (Barrett and Andrulis, 1992) . However, whether the ability of agents that break DNA to stimulate breaks, a property that characterizes loci defined as drug-sensitive "fragile sites" (Sutherland, 1979 ; Yunis amplification is general, whether the clastogenic drugs identified as amplification inducers operate through a and Soreng, 1984; Yunis et al., 1987; Sutherland and Richards, 1995) . Remarkably, induction of intrachromocommon mechanism, and whether the same agents can induce both BFB cycles and extrachromosomal amplifisomal ampd2 and dhfr gene amplification was found associated with the presence of nearby drug-activated cation remain to be determined.
We have reevaluated here the ability of different telomeric fragile sites. Moreover, the localization of distal and proximal fragile sites bracketing the mdr1, agents to induce amplification through intrachromosomal or extrachromosomal pathways. We first analyzed ampd2, and dhfr genes accounts in a simple manner for the structural peculiarities of amplified units generthe early stages of multi-drug resistance 1 (mdr1) gene amplification since several different drugs can be used ated at each of these loci during the initial stages of amplification. The results presented establish that siteto select mutants amplified for the same gene (for a review, see Veinot and Ling, 1992) . Three selective specific breaks triggered by fragile site inducers account for the early features of intrachromosomal amplification. agents-adriamycin (ADR), actinomycin D (AMD), and vinblastin (VB)-were chosen to screen for mutants of the GMA32 Chinese hamster cell line. ADR and AMD Results are DNA-damaging agents, known to induce p53 accumulation (Fritsche et al., 1993; Nelson and Kastan, 1994) , Recovery of Early Mutant Clones Resistant to ADR, AMD, or VB while VB, a spindle poison, is not expected to have clastogenic properties and does not induce p53 (Nelson To analyze independent resistant clones at a stage allowing the unequivocal identification of the molecular and Kastan, 1994) . We found that only AMD induces mdr1 gene amplification and that only the BFB cycles amplification mechanism(s) governing multidrug resistance, a protocol for the recovery of early mutants was mechanism is significantly enhanced by this drug. We discovered that, at the drug concentrations used to seadapted from the method described by Smith et al. (1990) : eight cell subpopulations, small enough (50 cells) lect the amplified mutants, ADR is a powerful but random to be statistically devoid of preexisting resistant mual., 1988) and P3C4, a telomeric marker for chromosome 1q (Toledo et al, 1992b ; Figure 4B ). Some clones, setants, were isolated and independently expanded to lected for resistance to ADR or AMD, identified by dot 5.10 6 cells in nonselective medium. Aliquots of cells from blot analysis as weakly amplified, were polysomic for each subpopulation were then independently plated in chromosome 1 (Table 1) . Since these mutants result selective media containing ADR, AMD, or VB, each drug from neither BFB cycles nor DM formation, they will not known to select for mdr1 gene amplification, but only be discussed further. Other clones exhibited a higher the first two being clastogenic. Three concentrations of copy number of the mdr1 gene. In some of them, the each agent were used in parallel to adjust the selection great majority of cells contained DMs, frequently bearing stringencies. Seven of the initial subpopulations yielded more than one copy of the mdr1 gene and two normal a comparable small number of clones in the three drugs. chromosomes 1, with no cytogenetically detectable alHowever, the last subpopulation (designated 8) gave teration other than the deletion of one chromosomal confluent plates in all three drugs after 5 days, sugcopy of the mdr1 gene ( Figure 2 ). These observations gesting that it contained a resistant mutant that had appeared prior to selection. Resistant cells of subpopulation 8 were pooled and analyzed by FISH. All were diploid with unrearranged chromosomes 1 and contained DMs bearing the mdr1 gene, independently of the drug used for selection. This result suggests a clonal origin of the resistant cells, supporting the hypothesis that subpopulation 8 contained a preexisting mutant.
Resistant clones from the seven other subpopulations were recovered and independently expanded in their original selective medium for a few more generations before analysis. We examined 37, 30, and 19 clones resistant to VB, ADR, and AMD, respectively (Table 1) . Dot blot and cytological analyses revealed that the mdr1 gene was unamplified in some resistant mutants (not shown). Such clones were recovered from cells selected with AMD, ADR, or VB, and some were cross-resistant to the three drugs. They were not further studied and the mechanism of their resistance is unknown, but crossresistance most likely results from overexpression or mutation of the mdr1 gene or of a related gene involved in multidrug resistance (Veinot and Ling, 1992; Gottesman et al., 1995 Gottesman et al., , 1996 . The ratio of the unamplified mutants to the total number of mutants depended strikingly on the selective agent: they represented the great majority of resistant clones that grew in the presence of VB (94.6%) and ADR (83.3%), but the minority of those that grew in the presence of AMD (31.6%) ( Table 1) . These results identify AMD as the only potent inducer of amplification among the three drugs tested. gene (which maps at 1q26) (Sen et al., 1987 ; Biedler et distributed with comparable frequencies as products of intrachromosomal and extrachromosomal amplification mechanisms (Table 1) . In striking contrast, all of the highly amplified clones (10/10) recovered after selection with AMD displayed products of BFB cycles. We considered the possibility that cells containing DMs could be counterselected in AMD or, on the contrary, that cells containing intrachromosomal copies of the mdr1 gene could be counterselected in VB and ADR. Cells of subpopulation 8 (which show DMs when selected with all three drugs) exhibited a normal growth rate in AMD when compared to VB or ADR. Moreover, the two clones with extrachromosomal mdr1 amplification recovered from the other subpopulations after selection with VB or ADR also exhibited a normal growth rate when checked for cross-resistance to AMD. No selection against cells containing intrachromosomal copies of the mdr1 gene selected in AMD was noticed during subsequent growth in VB or ADR. Taken together, our results indicate that AMD specifically induces the generation of mdr1 amplification by initiating BFB cycles.
DNA Breaks Induced by the Clastogenic Drugs ADR and AMD
To understand the striking difference in the properties of ADR and AMD, we investigated the damages imposed It probably corresponds to the Chinese hamster chrocleus, indicating that one of the two copies of this locus has been lost; this confirmed that the BFB mechanism is operating in these mosome 1 fragile site located at 1q26-31 (Rassool et al., cells. 1991). In contrast, in ADR-treated cells, multiple breaks distributed at random from cell to cell were observed favor a looping-out mechanism for DM formation, as with no preferential location. In experiments performed previously proposed from analysis of ampd2 gene amwith lower concentrations of ADR, giving rise to only plification (Toledo et al., 1993) . Such clones were refew breaks per cell, no evidence for preferential breakcorded as products of extrachromosomal amplification, age sites was obtained either (not shown). The specific although reintegration of extra copies was observed in ability of AMD to activate the expression of fragile sites, some metaphases (not shown). Only a few clones were particularly site (a), provides an explanation for its ability amplified by this extrachromosomal process: 1/37 in to stimulate the initiation of mdr1 intrachromosomal amselection with VB, 1/30 with ADR, and 0/19 with AMD plification. Moreover, the fluorescence intensity of each (Table 1) .
rung of the mdr1 ladders is systematically higher than The remaining clones exhibited intrachromosomal the fluorescence intensity of the normal locus (Figure amplification. They contained a single copy of P3C4 on 3A), suggesting that each rung represents more than the unamplified chromosome 1 and ladders of extra one mdr1 copy. This observation is consistent with initicopies of mdr1 on the other chromosome 1, the teloation of the process by a break close to the selected meric part of which was deleted ( Figure 3A ). Occasiongene, since each rung would then be a doublet of mdr1 ally, metaphases contained fused sister chromatids copies. bearing the amplified mdr1 genes ( Figure 3B ) or an amplified chromatid forming a bridge between two ana-
Coformycin Induces Breaks at Fragile Sites phase-telophase genomes (not shown). Bridges bearing
Close to the ampd2 Gene the amplified copies of mdr1 were also observed beUsing the same cell line, we have previously selected tween interphase nuclei containing a high level of mdr1 mutants resistant to coformycin, an adenosine analog amplification ( Figure 3C ). These observations show that that acts as an inhibitor of adenylate-deaminase activity. BFB cycles operate in these clones.
No mechanism of resistance other than ampd2 gene Screening of the few highly amplified clones recovered after VB or ADR selections showed that they were amplification has been detected in the large number of mutants tested and, with few exceptions, amplification proceeded by the BFB mechanism (Toledo et al., 1992a (Toledo et al., , 1992b . The situation disclosed by the analysis of the mdr1 system encouraged us to check for the existence of a coformycin-activated fragile site telomeric to the ampd2 gene. As represented in Figure 4B , coformycin induces breaks at sites colocalized with those activated by AMD, within the limits of precision of the mapping technique. Among them, the (b) site, telomeric to the ampd2 gene (Figure 4Ab ), is expressed most frequently following the coformycin challenge (13% of informative mitoses) ( Figure 4B ). Thus, the break induced at site (b) again accounts for the triggering of amplification by BFB cycles of a gene centromeric to this fragile site. The frequent coamplification of ampd2 and P3C4 during BFB cycles (Toledo et al., 1992b) could result from the existence of site (f), another coformycin-inducible fragile site centromeric to P3C4 (Figure 4Af ). Indeed, induction of fragile site (f) cannot initiate intrachromosomal ampd2 amplification since the gene, like any marker telomeric to the break, would be deleted. Induction of this site could instead efficiently resolve a bridge between sister chromatids fused at site (b) ( Figure 5A ). The two fragile sites flanking the ampd2 locus would then define the size and organization of the first amplified unit. The rungs of ampd2 gene copies appear as doublets because they are separated by twice the very short distance between ampd2 and site (b). The next cell cycle leads to formation of a dicentric chromatid bearing two ampd2 doublets, separated from each other by twice the distance between ampd2 and fragile site (f). Repeated breaks at sites (f) accumulate repeats of these large units, giving rise to regular ladders of ampd2 doublets on the amplified chromatid. Remarkably, the type of rearrangements predicted by this model explains entirely the generation of the regular repeats observed early in the amplification process, as well as the constant size of the repeats in independent clones during the very first stages of ampd2 amplification (Toledo et al., 1992a) (Figure 5B ). The induction of fragile site (f) is expected to stop as soon as accumulation of a sufficiently large number of ampd2 gene copies relieves the metabolic pressure leading to its activation. During subsequent cell divisions, BFB cycles may be perpetuated by breakage of the bridge at random positions, leading to an increase in the heterogeneity of the amplified units, as observed in cells with a relatively high copy number of the ampd2 gene (Toledo et al., 1992a ).
In the model just described, we considered the case . FISH with a P3C4 probe identifies chromosome 1q. (e): the red arrow points to the telomeric part of chromosome 1a containing P3C4. As previously reported (Toledo et al., 1992) , the distance between P3C4 and the telomere AMD on chromosome 1. Each red oval represents 1% of mitoses is longer on the 1a than on the 1b homolog. (f): as in (e), one P3C4 with a break at the corresponding site. At least 250 informative is on a normal chromosome 1b and the other is on a broken fragment mitoses were analyzed for each drug. Yellow rectangle: mdr1 gene; of chromosome 1a.
white rectangle: P3C4; black rectangle: ampd2 gene. chromosome 7, telomeric to the cad gene, which could initiate its amplification (not shown). On chromosome 2, two fragile sites telomeric to the dhfr gene could trigger its amplification through BFB cycles, and a centromeric site could resolve the fused chromatids ( Figure  6A ). In this system, the two fragile sites that can initiate the process are close together but far from the selected gene, telomeric to the dark DAPI band specific for Chinese hamster chromosome 2 ( Figure 6A ). This accounts remarkably well for the large distance separating the dhfr gene at its wild-type location from the first extra copy ( Figures 6B and 6C ). FISH and banding experiments showed that this large duplication is an inverted repeat ( Figure 6C ). FISH with probes for the dhfr gene and a marker close to the 2p telomere (II6) showed that this marker is deleted on the chromosome arm bearing dhfr ladders (not shown). These observations are completely explained by BFB cycles starting at a fragile site telomeric to the dark DAPI band. Moreover, we observed two slightly different types of large inverted repeats, corresponding to the two possible initiator sites. These were characterized by a different length of the DAPI ϩ band flanked by the two short symmetrical dark bands (not shown). In most early amplified mutants, localization of the third dhfr gene copy of the ladder ( Figure 6C3 ) is explained perfectly by a break at fragile site (ce). contrast to VB, ADR and AMD are clastogenic intercalating agents. Only AMD is a potent inducer of amplification, while VB and, surprisingly, ADR select for but do not doublet, is broken at stage B2, the break will lead to a induce mdr1 amplification. In the rare amplified mutants ladder with an odd number of doublets, and may contribresistant to ADR or VB, the extrachromosomal and inute to the formation of a ladder with three rungs (Fig- trachromosomal mechanisms appear at comparable ure 5B2).
frequencies. Strikingly, none of the amplified clones recovered from AMD selection exhibited extrachromosomal-amplified mdr1 copies. Three clones were poly-MTX Induction of Fragile Site Expression and Gene Amplification somic for chromosome 1, and ten presented the characteristic features of BFB cycles ( Figures 3A-3C ). It has been demonstrated that pretreatment with MTX increases the frequency of mutants resistant to MTX, Thus, most, if not all, AMD-induced amplified mutants resulted from the BFB mechanism. This property was ADR, and PALA by amplification of the dhfr, mdr1, and cad genes, respectively (Rath et al., 1984; Tlsty et al., correlated with the ability, unique to AMD, to induce expression of a fragile site telomeric to the mdr1 gene. 1984; Kuo et al., 1994; Poupon et al., 1996) . To evaluate how general the involvement of fragile sites in the inducThe expression of fragile sites telomeric to the selected gene was also examined at other loci, the amplification tion of intrachromosomal amplification may be, we examined the pattern of breaks induced by MTX.
of which is usually selected with clastogenic drugs (ampd2/coformycin, dhfr/MTX). The conclusion in all We focused on chromosome 1, which bears the mdr1 and ampd2 genes, and on chromosomes 2 and 7, which cases examined is that the drugs induce fragile sites at locations that can trigger the amplification of the sebear the dhfr and cad genes, respectively. Strikingly, MTX-induced sites on chromosome 1 appear to be cololected genes. The redundant character of such a correlation strongly supports the simple hypothesis that these calized with those described in Figure 4B . Among them, sites (a) and (b), involved respectively in AMD-and cofordrugs induce intrachromosomal amplification because they activate the expression of fragile sites telomeric to mycin-induced amplification, were found to be also activated by MTX. Moreover, we identified a fragile site on the selected gene.
Breaks induced by AMD and coformycin on chromosome 1 are colocalized, and most of them comap with those revealed by the use of aphidicolin or MTX in other studies (Rassool et al., 1991; Kuo et al., 1994) , suggesting that the same fragile sites are induced by these different drugs. This offers an explanation for previous results showing that short pretreatment of cells with MTX increased the frequency of mutants amplified for dhfr (Rath et al., 1984; Tlsty et al., 1984) , mdr1 (Kuo et al., 1994) , and cad genes (Poupon et al., 1996) . Indeed, some of the MTX-inducible fragile sites that we mapped on chromosomes 1, 2, and 7 are appropriately located to trigger the amplification of the mdr1, dhfr, and cad genes, respectively. In the CHO cell line, a possible contribution of one of these sites to mdr1 amplification has been proposed (Kuo et al., 1994) . Pretreatment with PALA has also been proven to increase the frequency of amplified mutants resistant to MTX or PALA (Poupon et al., 1996) . This suggests that PALA is also able to activate the same fragile sites as the drugs we have studied.
Breakpoints at Telomeric and Centromeric Fragile Sites Frame the Initial Intrachromosomal Amplicons
We obtained striking evidence that breaks at fragile sites control the initial steps of intrachromosomal amplification at different loci. Because the BFB mechanism leads to a progressive accumulation of extra copies of a gene during clonal cell expansion, the fragile sites will remain activated until enough copies to overcome the toxic effects of the selective drug are acquired. Thus, the sequential induction of two fragile sites flanking the selected gene can define the size of the amplified units and the distribution of marker genes along the amplified plications observed here and in previous studies on CHO (te) : break at fragile site telomeric to the dhfr gene. DAPI staining; cells (Ma et al., 1993) . In all three systems examined, symbols as in (ce).
the secondary activation of a site centromeric to the tions with breakpoints at fragile sites are well docuoccuring during the third cycle, leading to the ladder shown in (C3). The other features are as described in Figure 5A . Chromosome 2q mented in cultured cells (Warren et al., 1987; Glover is not drawn to scale. and Stein, 1988) . Thus, gene amplification is another in cells with a relatively high copy number of the ampd2 (Toledo et al., 1992a) or mdr1 and dhfr genes. Moreover, we observed bridges between anaphase-telophase nuin determining the size and genetic content of amplified clei, but never between interphase nuclei, of daughter units at an early stage of drug-selected amplification. cells carrying only a few copies of the selected gene.
Because the amplification of oncogenes is frequently On the contrary, bridges like those shown in Figure 3 observed in tumor cells, it is of special interest to deterwere observed frequently in cells with a high copy nummine whether fragile sites are at the origin of breaks in ber of the amplified gene, suggesting that resolution of the organism. Recently, Jacobsen Syndrome has been the dicentromeric chromatid is delayed in these cases.
related to fragile site FRA11B, the activation of which These cytological features support the idea that at least leads to the deletion of the CBL2 proto-oncogene (Jones two breakage mechanisms operate in sequence during et al., 1995) . The hypothesis that activation of fragile the amplification process, and that their relative utilizasites could be responsible for the recurrent chromotion is controlled by the copy number of the selected somal rearrangements identified in some cancers was gene.
proposed more than ten years ago (Yunis, 1983 ; Lebeau An expected consequence of the coexpression of sevand Rowley, 1984; Yunis and Soreng, 1984) , and evieral fragile sites in early mutants is the induction of dence that fragile site FRA3B is involved in the deletion chromosome rearrangements. During amplification, ring of the FHIT tumor suppressor gene has recently been and dicentric chromosomes are observed at a strikingly obtained (Ohta et al., 1996; Sozzi et al., 1996) . Taken high frequency from very early stages (Smith et al., together, these results suggest that fragile sites can be 1992). We discussed previously the likely role of addiactivated in vivo and can trigger targeted chromatid tional breakage events to generate these structures from breaks. To evaluate the role of fragile sites in the initiachromosomes undergoing BFB cycles, but the origin of tion of oncogene amplification in tumors, we consulted such additional breaks was not explained (Toledo et al., the Genome Data Bank in an attempt to compare the 1993). The coactivation of multiple fragile sites supplies locations of fragile sites with those of oncogenes amplia likely explanation for the generation of these early fied frequently in different cancers. Such an analysis is rearrangements.
necessarily limited by the fact that not all fragile sites are localized precisely or even recorded, nor are all the Mutants Not Induced by the Selective Agent gene maps reliable. Moreover, analysis of the amplificaOur study raises the question of whether additional coption process in tumor cells is obscured by secondary ies of a gene can be acquired by the same mechanisms rearrangements, as in advanced mutants isolated in without induction by the selective drug. This question vitro. We focused on the 11q13 and 12q13-14 loci, behas been addressed previously in the cad system, where cause these regions contain gene clusters allowing an it was strongly suggested that BFB cycles operate in analysis of coamplification patterns, and amplification both cases (Poupon et al., 1996) . We show here that the by BFB cycles is suggested in some cases by localizaintrachromosomally amplified mutants obtained with tion of the extra copies on the chromosome arm bearing ADR and VB exhibit cytological features typical of the the locus in normal cells (Roelofs et al., 1993 ; Lese et operation of BFB cycles and that the amplified strucal, 1995) or by their symmetrical organization (Pedeutour tures observed in these mutants were remarkably similar et al., 1994) . At the 11q13 locus are linked the genes to those revealed in induced mutants. Indeed, doublets encoding the B cell CLL/lymphoma (BCL1), cyclin D1 of the mdr1 gene were present in each rung of the lad-(CCND1/PRAD1), fibroblast growth factor types 3 and ders, indicating that the initiating break occurred very 4 (FGF3/INT2 and FGF4/HSTF1), the cortactin protein close to the selected gene. This is consistent with initia-(EMS1), and the glycoprotein A repetition predominant tion at the same fragile site as in induced mutants, which (GARP). These genes are frequently coamplified in could have been activated in these cases by some unbreast, head, and neck carcinomas, in oral squamous controlled stress imposed on the cells.
cell carcinomas, and in other cancers (Schuuring, 1995) . We also showed that the frequency of extrachromoThis gene cluster is flanked by two fragile sites: FRA11F somal events is not enhanced upon selection in ADR or (11q14.2) and FRA11A (11q13.3). Another fragile site not AMD as compared to VB. Since we verified that cells yet precisely mapped, FRA11H (11q13) could also be containing DMs are not strongly counterselected in the involved in the amplification process. The 12q13-q14 two clastogenic drugs, our results show that neither region is frequently amplified in glioblastomas (Collins, AMD-induced site-specific breaks at fragile sites nor 1995) and in other cancers such as liposarcomas. Sev-ADR-induced breaks at random stimulate formation of eral genes at this locus were coamplified frequently, DMs in this system. These observations support the including the glioma-associated oncogene homolog hypothesis that intrachromosomal and extrachromo-(GLI), DNA damage-inducible transcript 3 (DDIT3/ somal amplifications follow independent pathways (To-GADD153), cyclin-dependent kinase 4 (CDK4), sarledo et al., 1993) , the products of which were observed coma-amplified sequence (SAS), and human homolog at roughly similar frequencies in mutants selected with of mouse double minute 2 (MDM2) genes. In this case, ADR or VB (Table 1) . The latter result suggests that amplification could be initiated at FRA12B (12q21.3), in model systems of drug-selected amplifications, the and the size of the amplicon determined by FRA12A contribution of the BFB mechanism has probably been (12q13.1). overestimated because the agents used to select muThese data are consistent with the possibility that tants induce this mechanism specifically.
amplification San et al., 1987; Chen et al., 1989; Ban et al., 1995 (1992) . Asparagine Synthetase Gene been previously described (Debatisse et al., 1982 (Debatisse et al., , 1984 . The method Amplification in Albizziin-Resistant Hamster and Human Cell Lines. used to observe cells at early stages of gene amplification is derived
In Gene Amplification in Mammalian Cells -A Comprehensive Guide, from Smith et al. (1990) . For the mdr1 selection, subpopulations of R.E. Kellems, ed. (New York: Marcel Dekker Inc.), pp. 119-129. 50 cells were plated in separate dishes and grown in regular medium Bertoni, L., Attolini, C., Tessera, L., Mucciolo, E., and Giulotto, E. for about 12 generations. Each subpopulation was then plated in (1994) . Telomeric and nontelomeric (TTAGGG)n sequences in gene selective medium containing VB (15 or 19 ng/ml), ADR (188, 206, or amplification and chromosome stability. Genomics 24, 53-62. 223 ng/ml), or AMD (88, 100, or 113 ng/ml). The same procedure was followed for the recovery of clones resistant to coformycin (0.5 Biedler, J.L., Chang, T.D., Scotto, K.W., Melera, P.W., and Spengler, or 0.7 g/ml) or MTX (9 or 18 ng/ml). Drug-resistant colonies were B.A. (1988) . Chromosomal organization of amplified genes in multirecovered and expanded to 10 5 cells before cytogenetic analysis. drug-resistant Chinese hamster cells. Cancer Res. 48, 3179-3187. Exponentially growing cells were treated with colcemid (100 ng/ml) Bishop, J.M. (1991) . Molecular themes in oncogenesis. Cell 64, or nocodazole (10 M) for 2-4 hr, then spread on slides as previously 235-248. described (Toledo et al., 1992a) and used for FISH studies. Brison, O. (1993) . Gene amplification and tumor progression. Biochim. Biophys. Acta 1155, 25-41.
Fragile Sites Induction
Carroll, S.M., Gaudray, P., DeRose, M.L., Emery, J.F., Meinkoth, Exponentially growing GMA 32 cells (5.10 5 cells per 10 cm diameter J.L., Nakkim, E., Subler, M., VonHoff, D.D., and Wahl, G.M. (1987) . petri dish) were treated with the drugs to be studied as previously
Characterization of an episome produced in hamster cells that amdescribed (Robinson and Elder, 1987; Yunis et al., 1987) . Briefly, plify a transfected CAD gene at high frequency: functional evidence cells were incubated for 18 hr in medium supplemented with VB, for a mammalian replication origin. Mol. Cell. Biol. 7, 1740-1750. ADR, AMD, coformycin, or MTX at the drug concentrations used to Champeme, M.H., Bieche, I., Lizard, S., and Lidereau, R. (1995). select mutants, then allowed to recover in normal medium for 8 hr, 11q13 amplification in local recurrence of human primary breast including the final 2 hr of incubation with nocodazole. Decreasing cancer. Genes Chromosom. Cancer 12, 128-133. concentrations of ADR (200, 150, 100, 50 ng/ml) were also tested.
Chen, A.T., Reidy, J.A., Annest, J.L., Welty, T.K., and Zhou, H.G. (1989) . Increased chromosome fragility as a consequence of blood In Situ Hybridization and Giemsa-Trypsin Banding folate levels, smoking status, and coffee consumption. Environ. Mol. FISH was performed essentially as described (Pinkel et al., 1988; Mutagen 13, 319-324. Tkachuk et al., 1990 ) with minor modifications (Toledo et al., 1993) . Collins, V.P. (1995) . Gene amplification in human gliomas. Glia 15, Lambda Charon 4A clones F 4-2 and R 97 (kind gifts of R. Zastawny 289-296. and V. Ling) were used to probe the mdr1 locus; cosmids KP 454 and KZ 381 (kind gifts of J. Hamlin), to probe the dhfr locus; cosmids Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B., and Bachetti, S. (1992). Telomere shortening C64 and C81 (kind gifts of G. Stark and E. Giulotto), to probe the cad locus; and cosmids 61W14, 56D3S1A1, and 56Y1B1, to probe associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921 EMBO J. 11, -1929 . the ampd2 locus (Debatisse et al, 1988) . Cosmids P3C3 and P3C4,
